Table 3.
Uni- and multivariate analysis of risk factors for appearance or development of PVST after PSE in the 67 patients
| Variables | No. of patients | No. without appearance or growth of PVST after PSE | No. with appearance or growth of PVST after PSE | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|---|
| p value | OR (95% CI) | p value | OR (95% CI) | ||||
| Age | 0.3056 | ||||||
| Sex | 1.0000 | 0.9 (0.237–3.579) | |||||
| Male | 46 | 40 | 6 | ||||
| Female | 21 | 18 | 3 | ||||
| Platelet count | 0.0507 | 0.2663 | 0.752 (0.455–1.243) | ||||
| Prothrombin time | 0.5911 | ||||||
| Total bilirubin | 0.5518 | ||||||
| Albumin | 0.4868 | ||||||
| ALT | 0.4203 | ||||||
| Hepatic encephalopathy | 1.0000 | 0.512 (0.026–10.041) | |||||
| Presence | 5 | 5 | 0 | ||||
| Absence | 62 | 53 | 9 | ||||
| ALBI score | 0.5161 | 0.0725 | 47.820 (0.702–3235.2) | ||||
| Hepatocellular carcinoma | 0.4465 | 2.292 (0.158–16.82) | |||||
| Presence | 4 | 3 | 1 | ||||
| Absence | 63 | 55 | 8 | ||||
| Occlusion or thrombus of the portal venous system before PSE | 0.0601 | 4.444 (1.15–17.22) | 0.0539 | 10.665 (0.962–118.29) | |||
| Presence | 24 | 18 | 6 | ||||
| Absence | 43 | 40 | 3 | ||||
| Pre-PSE maximum diameter of the splenic vein | 0.0076 | 0.0409 | 1.535 (1.018–2.315) | ||||
| Pre-PSE total splenic volume | 0.1528 | ||||||
| Infarcted splenic volume | 0.0216 | 0.0886 | 0.995 (0.989–1.001) | ||||
| Infarcted splenic percentage | 0.0171 | 0.0230 | 1.136 (1.018–1.267) | ||||
| Steroid used for pain management | 0.4661 | 2.3 (0.487–11.6) | |||||
| Used | 25 | 23 | 2 | ||||
| Not used | 42 | 35 | 7 | ||||
| Heparin used after PSE | 0.1249 | 0.275 (0.057–1.208) | 0.1336 | 10.746 (0.483–239.20) | |||
| Used | 10 | 7 | 3 | ||||
| Not used | 57 | 51 | 6 | ||||
PVST portal venous system thrombosis; PSE partial splenic artery embolization; ALT alanine aminotransferase; ALBI albumin-bilirubin;